•
Dec 31, 2020

22nd Century Group Q4 2020 Earnings Report

22nd Century Group's Q4 2020 financial results were announced, with net sales revenue consistent with the prior-year period and gross profit improving.

Key Takeaways

22nd Century Group reported net sales revenue of $7.3 million for Q4 2020, consistent with the prior-year period. The company's gross profit improved, while the net loss increased. The company is focused on securing Modified Risk Tobacco Product (MRTP) authorization for VLN® and advancing its hemp/cannabis strategy.

Net sales revenue for the fourth quarter was $7.3 million, consistent with the prior-year period.

Gross profit for the fourth quarter improved by $364 thousand.

Net loss increased by $207 thousand for the fourth quarter.

The company's balance sheet is well funded with $22.3 million at the end of the year.

Total Revenue
$7.3M
Previous year: $7.3M
+0.0%
EPS
-$12
Previous year: -$12
+0.0%
Adjusted EBITDA
-$5.38M
Gross Profit
$588K
Previous year: $225K
+161.6%
Cash and Equivalents
$22.3M
Previous year: $485K
+4497.9%
Free Cash Flow
-$3.02M
Previous year: -$3.42M
-11.7%
Total Assets
$51.7M
Previous year: $69M
-25.0%

22nd Century Group

22nd Century Group

Forward Guidance

22nd Century Group is focused on securing FDA authorization for VLN®, supporting the FDA’s plan to require all cigarettes sold in the U.S. to be made “minimally or non-addictive”, targeting the upstream segment of the cannabinoid value chain, developing a third, plant-based franchise after securing MRTP authorization for VLN®, and maintaining diligent financial execution.

Positive Outlook

  • Securing FDA authorization for VLN®.
  • Supporting the FDA’s plan to require all cigarettes sold in the U.S. be made “minimally or non-addictive”.
  • Targeting the upstream segment of the cannabinoid value chain.
  • Creating proprietary, commercially valuable new plant lines and related intellectual property with stabilized genetics to harness and optimize hemp/cannabis plant potential.
  • The Company expects to monetize a portion of its existing hemp/cannabis IP in 2021 and will continue to bring disruptive technology forward.

Challenges Ahead

  • No specific negative guidance was provided in the document.
  • Forward-looking statements are subject to risks and uncertainties.
  • Actual results might differ materially from those explicit or implicit in forward-looking statements.
  • Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Form 10-K filed on March 11, 2021.
  • The Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.